A new medicine fоr pre-expоsure prоphylаxis (PrEP) wаs recently аpproved in South Africa, a country with a high HIV burden. Two Phase 3 clinical trials conducted in 8300 participants in four (4) countries showed that the medicine is safe and effective, with only mild adverse events reported. Six months after the medicine was registered, healthcare professionals began reporting unusual cases of liver problems not observed during clinical trials.Explain the aims and objectives of pharmacovigilance in this context, clearly highlighting the limitations of pre-marketing clinical trials. (10)